PUBLIC COMPANY
save$DFTXDefinium Therapeutics, Inc.
$DFTX38.06-0.39%New York, NY, USupdated 17h ago
Definium Therapeutics, Inc., formerly known as MindMed, is a New York-based biotechnology company that is currently developing clinical and therapeutic applications for psychedelic and, more broadly, psychoplastogenic drugs.
community read0 votes
pipeline
1
marketed
0
phase 3
1
catalysts ytd
1
approvals ytd
0
recalls ytd
0
Pipeline(1)
pipeline depth1 products
1Phase 3
Upcoming
no upcoming catalysts on record
Recent(90d)
earnings (1)
🐶 Hiring Signal
News
- Psychedelic therapies ride wave of public favor into FDA hearingHeading into an FDA hearing on Monday regarding the future of psychedelic treatments, public comments show wide support for further exploring the therapeutic potential of these compounds—to match r…biospace · 17d ago
- ‘A rising tide scenario’: Why other Big Pharmas could follow Lilly into psychedelicsAfter Eli Lilly dived into the psychedelics space with a $2.8 billion upfront acquisition of AtaiBeckley last week, industry experts told Fierce that the deal would give the space added momentum.fiercebiotech · 2mo ago
- Lilly to buy AtaiBeckley for $2.8B, further validating psychedelicsThe latest in a prolific streak of buyouts by Lilly is the strongest sign yet that large pharmaceutical companies may finally be embracing a long-dismissed field of research.biopharma_dive · 2mo ago
Data sources
last refreshed 22m ago
Found something off?
comments(0)
5-min edit window · permanent after that